Last 7 days
-4.3%
Last 30 days
-13.8%
Last 90 days
-1.5%
Trailing 12 Months
-32.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 127.1B | 26.3B | 0.79% | 2.78% | 19.4 | 4.83 | 1.32% | 11.18% |
GILD | 99.8B | 27.3B | -4.19% | 39.66% | 21.72 | 3.66 | -0.09% | -26.23% |
MRNA | 58.1B | 19.3B | -4.61% | -16.03% | 6.95 | 3.02 | 4.29% | -31.47% |
BIIB | 39.0B | 10.2B | -0.92% | 26.77% | 12.8 | 3.83 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.4B | 1.5B | -5.59% | 3.19% | 60.62 | 6.29 | 31.34% | 72.43% |
DNLI | 3.1B | 108.5M | -21.66% | -32.82% | -9.55 | 28.71 | 122.90% | -12.19% |
BBIO | 2.2B | 107.9M | 21.83% | 38.60% | -4.63 | 20.79 | 54.84% | 17.36% |
BEAM | 2.2B | 60.9M | -25.55% | -48.21% | -7.49 | 35.56 | 17.51% | 22.00% |
SMALL-CAP | ||||||||
RCUS | 1.3B | 112.0M | -7.70% | -49.25% | -4.81 | 11.47 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -17.00% | 22.02% | -7.14 | 159.78 | 131.81% | -45.39% |
FATE | 524.4M | 96.3M | -14.58% | -86.07% | -1.86 | 5.45 | 72.44% | -32.79% |
NVAX | 519.7M | 2.0B | -33.63% | -92.58% | -0.79 | 0.26 | 72.89% | 62.27% |
SGMO | 276.9M | 111.3M | -42.96% | -71.96% | -1.44 | 2.49 | 0.54% | -7.86% |
VXRT | 101.6M | 107.0K | -17.23% | -85.52% | -0.94 | 949.93 | -88.00% | -52.91% |
IBIO | 26.0M | - | 40.00% | -84.44% | -0.32 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -99.5% | 1,198,000 | 229,639,250 | 458,080,500 | 686,521,750 | 914,963,000 |
Operating Expenses | -3.9% | 674,359,000 | 701,409,000 | 648,600,000 | 603,265,000 | 541,435,000 |
S&GA Expenses | -2.4% | 102,464,000 | 104,973,000 | 101,681,000 | 104,214,000 | 99,690,000 |
R&D Expenses | 0.1% | 461,645,000 | 461,185,000 | 428,063,000 | 387,172,000 | 340,567,000 |
EBITDA | 3.5% | -626,328,000 | -649,363,000 | -601,681,000 | 337,710,000 | - |
EBITDA Margin | -18388.6% | -522 | -2.83 | -0.66 | - | - |
Earnings Before Taxes | 3.5% | -650,500,000 | -673,950,000 | -626,574,000 | 316,510,000 | 379,531,000 |
EBT Margin | -18401.6% | -542 | -2.93 | -0.68 | - | - |
Net Income | 4.5% | -650,175,000 | -680,848,000 | -633,452,000 | 311,607,000 | 377,661,000 |
Net Income Margin | -18205.0% | -542 | -2.96 | -0.69 | - | - |
Free Cahsflow | -4.8% | -532,929,000 | -508,631,000 | -515,774,000 | 414,365,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -4.7% | 2,243 | 2,353 | 2,463 | 2,606 | 2,752 |
Current Assets | -4.1% | 1,853 | 1,933 | 2,107 | 2,261 | 2,418 |
Cash Equivalents | -57.1% | 212 | 494 | 497 | 684 | 923 |
Net PPE | -1.5% | 164 | 166 | 165 | 157 | 138 |
Liabilities | -8.0% | 368 | 399 | 373 | 361 | 352 |
Current Liabilities | -19.7% | 121 | 151 | 120 | 114 | 120 |
Shareholder's Equity | -4.0% | 1,875 | 1,954 | 2,091 | 2,245 | 2,399 |
Retained Earnings | -15.0% | -846 | -735 | -560 | -375 | -195 |
Additional Paid-In Capital | 0.9% | 2,735 | 2,709 | 2,670 | 2,635 | 2,598 |
Accumulated Depreciation | -45.3% | 28.00 | 51.00 | 44.00 | 38.00 | - |
Shares Outstanding | 0.3% | 79.00 | 78.00 | 78.00 | 77.00 | 77.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -5.8% | -495 | -468 | -444 | 504 | 539 |
Share Based Compensation | -2.9% | 98.00 | 101 | 103 | 106 | 102 |
Cashflow From Investing | -181.6% | -258 | -91.84 | -744 | -982 | -1,035 |
Cashflow From Financing | -9.0% | 39.00 | 42.00 | 38.00 | 36.00 | 251 |
100%
88.1%
80%
Y-axis is the maximum loss one would have experienced if CRISPR Therapeutics AG was unfortunately bought at previous high price.
-3.9%
0.6%
FIve years rolling returns for CRISPR Therapeutics AG.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -17.56 | -257,125 | 269,875 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | sold off | -100 | -313,000 | - | -% |
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -8.73 | -8,151,780 | 10,705,200 | 0.01% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -15.37 | -2,952,000 | 3,283,000 | 0.02% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 25,813 | 25,813 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | reduced | -50.85 | -93,740 | 41,260 | 0.02% |
2023-02-28 | Voya Investment Management LLC | added | 1.23 | -529,457 | 899,543 | -% |
2023-02-24 | SRS Capital Advisors, Inc. | sold off | -100 | -3,000 | - | -% |
2023-02-21 | Boulder Wealth Advisors, LLC | new | - | 8,000 | 8,000 | 0.01% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -39.03 | -90,554 | 55,446 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital international investors | 7.1% | 5,560,492 | SC 13G | |
Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 5.11% | 4,006,476 | SC 13G/A | |
Feb 14, 2022 | nikko asset management americas, inc. | 5.64% | 4,319,471 | SC 13G/A | |
Feb 11, 2022 | capital international investors | 4.8% | 3,706,004 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 11.88% | 9,087,868 | SC 13G/A | |
Feb 04, 2022 | sumitomo mitsui trust holdings, inc. | 5.64% | 4,319,471 | SC 13G/A | |
Sep 10, 2021 | ark investment management llc | 10.03% | 7,644,350 | SC 13G/A | |
Aug 10, 2021 | capital international investors | 5.6% | 4,265,002 | SC 13G/A | |
Feb 16, 2021 | ark investment management llc | 14.62% | 10,412,976 | SC 13G/A | |
Feb 16, 2021 | capital international investors | 10.7% | 7,626,355 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 7.65 -82.39% | 8.24 -81.03% | 10.03 -76.91% | 12.82 -70.48% | 17.78 -59.06% |
Current Inflation | 7.53 -82.66% | 8.04 -81.49% | 9.62 -77.85% | 12.04 -72.28% | 16.32 -62.42% |
Very High Inflation | 7.37 -83.03% | 7.80 -82.04% | 9.12 -79.00% | 11.10 -74.44% | 14.60 -66.38% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 14, 2023 | 3 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 8-K | Current Report | |
Mar 01, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-13 | Kulkarni Samarth | sold (taxes) | -408,170 | 43.22 | -9,444 | chief executive officer |
2023-03-13 | KASINGER JAMES R. | sold (taxes) | -99,622 | 43.22 | -2,305 | general counsel and secretary |
2023-03-11 | KASINGER JAMES R. | acquired | - | - | 2,250 | general counsel and secretary |
2023-03-11 | Kulkarni Samarth | acquired | - | - | 9,000 | chief executive officer |
2023-03-10 | KASINGER JAMES R. | acquired | - | - | 2,833 | general counsel and secretary |
2023-03-10 | Kulkarni Samarth | acquired | - | - | 11,833 | chief executive officer |
2023-02-27 | Kulkarni Samarth | acquired | 478,000 | 19.12 | 25,000 | chief executive officer |
2023-02-27 | Kulkarni Samarth | sold | -1,206,240 | 48.2497 | -25,000 | chief executive officer |
2023-02-21 | Smith Brendan | sold (taxes) | -67,177 | 48.26 | -1,392 | chief financial officer |
2023-02-21 | Kulkarni Samarth | sold (taxes) | -307,561 | 48.26 | -6,373 | chief executive officer |
Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Total revenue | $ 1,198 | $ 914,963 | $ 719 |
Operating expenses: | |||
Research and development | 461,645 | 340,567 | 221,382 |
General and administrative | 102,464 | 99,690 | 85,747 |
Collaboration expense, net | 110,250 | 101,178 | 48,025 |
Total operating expenses | 674,359 | 541,435 | 355,154 |
(Loss) income from operations | (673,161) | 373,528 | (354,435) |
Other income | |||
Other income, net | 22,661 | 6,003 | 6,379 |
Total other income, net | 22,661 | 6,003 | 6,379 |
Net income (loss) before income taxes | (650,500) | 379,531 | (348,056) |
Benefit (provision) for income taxes | 325 | (1,870) | (809) |
Net (loss) income | (650,175) | 377,661 | (348,865) |
Foreign currency translation adjustment | (80) | (11) | 40 |
Unrealized loss on marketable securities | (10,500) | (4,973) | (130) |
Comprehensive (loss) income | $ (660,755) | $ 372,677 | $ (348,955) |
Net (loss) income per common share - basic | $ (8.36) | $ 4.97 | $ (5.29) |
Basic weighted-average common shares outstanding | 77,746,575 | 75,948,686 | 65,949,672 |
Net (loss) income per common share - diluted | $ (8.36) | $ 4.70 | $ (5.29) |
Diluted weighted-average common shares outstanding | 77,746,575 | 80,393,496 | 65,949,672 |
Collaboration Revenue [Member] | |||
Revenue: | |||
Total revenue | $ 436 | $ 913,081 | $ 543 |
Grant Revenue [Member] | |||
Revenue: | |||
Total revenue | $ 762 | $ 1,882 | $ 176 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 211,885 | $ 923,031 |
Marketable securities | 1,603,433 | 1,456,098 |
Accounts receivable | 0 | 305 |
Prepaid expenses and other current assets | 37,708 | 38,079 |
Total current assets | 1,853,026 | 2,417,513 |
Property and equipment, net | 163,634 | 137,575 |
Marketable securities, non-current | 53,130 | 0 |
Intangible assets, net | 71 | 125 |
Restricted cash | 11,635 | 16,913 |
Operating lease assets | 156,921 | 174,460 |
Other non-current assets | 4,640 | 5,291 |
Total assets | 2,243,057 | 2,751,877 |
Current liabilities: | ||
Accounts payable | 27,428 | 14,816 |
Accrued expenses | 77,682 | 91,003 |
Deferred revenue, current | 0 | 1,011 |
Accrued tax liabilities | 135 | 724 |
Operating lease liabilities | 15,842 | 12,158 |
Other current liabilities | 20 | 171 |
Total current liabilities | 121,107 | 119,883 |
Deferred revenue, non-current | 12,323 | 12,323 |
Operating lease liabilities, net of current portion | 228,179 | 212,872 |
Other non-current liabilities | 5,969 | 7,339 |
Total liabilities | 367,578 | 352,417 |
Commitments and contingencies (Note 9) | ||
Shareholders’ equity: | ||
Common shares, CHF 0.03 par value, 150,347,467 and 145,364,335 shares authorized at December 31, 2022 and 2021, respectively, 78,692,766 and 77,170,382 shares issued at December 31, 2022 and 2021, respectively, 78,512,450 and 76,990,066 shares outstanding at December 31, 2022 and 2021, respectively. | 2,441 | 2,391 |
Treasury shares, at cost, 180,316 shares at December 31, 2022 and 2021, respectively | (63) | (63) |
Additional paid-in capital | 2,734,838 | 2,598,114 |
Accumulated deficit | (846,090) | (195,915) |
Accumulated other comprehensive loss | (15,647) | (5,067) |
Total shareholders’ equity | 1,875,479 | 2,399,460 |
Total liabilities and shareholders’ equity | $ 2,243,057 | $ 2,751,877 |